Medical articles
A New Cyber Concern: Hack Attacks on Medical Devices
Personal Grooming Products May Be Harming Great Lakes Marine Life
Location May Stymie Wind and Solar Power Benefits
Lead Costs Developing Economies Nearly $1 Trillion Annually
Sweet ‘n Sour: A Common Sugar May Help Pathogens Conquer the Human Gut
NIH Will Curb Research on Chimps
Is Age the Main Factor in Nelson Mandela's Lung Infection?
Gut Microbes Spur Liver Cancer in Obese Mice
A Father's Genetic Quest Pays Off
EPA Defends Chemical Testing of Low-Dose Hormone Effects
Deadly piglet virus spreads to nearly 200 U.S. farm sites
E-cigarettes may help smokers quit, study suggests
Breast-fed children more likely to climb the social ladder
Weight loss doesn't reduce heart problems for some
Talking to teens about weight loss tied to unhealthy dieting, laxative use
5 ways to grill food safely
Menopause hormone use not linked with cognitive problems
Genes known to cause birth defects may also lead to mental illness
7 African countries cut child HIV infections by half
Woman drinks only soda for 16 years, suffers heart problems
Is iron deficiency causing psychiatric disorders in kids?
Common meds containing caffeine may be linked to stroke
Could Obama’s climate plan help decrease asthma rates?
Is raw milk safe to drink?
  New clot preventer works as well as warfarin with less bleeding
The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused far less bleeding, according to data from a large clinical trial.

The Pfizer and Bristol-Myers pill met the main goal of the study by showing it worked just as well as conventional treatment with warfarin, a generic blood thinner, in reducing recurrence of the condition and related deaths.

Eliquis also led to a nearly 70 percent reduction in the risk of major bleeding and more than a 50 percent reduction in a category known as clinically relevant non-major bleeding. Bleeding is typically the most troubling side effect of extended use of blood thinning drugs.

Dr. Giancarlo Agnelli, the study's lead investigator, called the bleeding results "a remarkable real advantage" for Eliquis.

"This is to me the most striking finding of this study in terms of potential changes to clinical practice," Agnelli, who presented the data on Monday at the International Society on Thrombosis and Hemostasis (ISTH) meeting in Amsterdam, said in a telephone interview. The results were also published in the New England Journal of Medicine.

"This really makes apixaban a really safe compound," he added, using the chemical name for Eliquis.

Venous thromboembolism (VTE) is a potentially fatal condition consisting of blood clots in the leg, known as deep vein thrombosis, and clots in the lungs, known as pulmonary embolism. About 900,000 Americans and 1 million patients in the European Union are diagnosed with the condition each year. The condition recurs in up to 10 percent of patients.


Eliquis belongs to a new class of blood clot preventers meant to replace warfarin, which has been in use for decades and requires rigorous monitoring. It competes directly with Xarelto from Bayer AG and Johnson & Johnson, and Boehringer Ingelheim's Pradaxa.

Some doctors have been reluctant to switch to the new medicines in part because their blood-thinning effect is not easily reversed in case emergency medical treatment, such as surgery, is needed. Companies are testing agents that could be used to reverse the blood thinning effect if necessary.

Eliquis is already approved to prevent strokes and blood clots in patients with a common, but dangerous irregular heartbeat known as atrial fibrillation - by far the largest market for the new blood thinners.

ISI Group analyst Mark Schoenebaum forecast eventual peak annual sales of $3 billion for the drug. If approved for venous thromboembolism, it would add an important, if smaller, use for the medicine.

While doctors are comfortable using warfarin, it requires careful patient monitoring of levels of the drug in the blood and dose adjustments, as well as patient dietary and lifestyle changes to prevent dangerous bleeding. Eliquis and its rivals are a fixed dose treatment with little or no patient monitoring required.

"Even if you show just non-inferiority, the advantage (of Eliquis) in terms of increased practicality is huge," said Agnelli, the director of the Department of Internal and Cardiovascular Medicine and Stroke-Unit of University Hospital in Perugia, Italy.

The nearly 5,400-patient trial tested 10 milligrams of Eliquis given twice a day for seven days followed by 5 mg twice daily for six months against the conventional use of initial injections of Sanofi's Lovenox (enoxaparin) followed by daily use of warfarin.

For the composite goal of recurrence of VTE and VTE-related death there were 59 cases for Eliquis, or 2.3 percent, versus 71 cases for warfarin, or 2.7 percent.

For the primary safety goal of the study, there were 15 reports of major bleeding among Eliquis patients, or 0.6 percent, compared with 49 major bleeds among warfarin patients, or 1.8 percent. The 69-percent reduced major bleeding risk was deemed to be highly statistically significant, researchers said.

There were 103 reported cases of clinically relevant non-major bleeding with the Pfizer and Bristol drug versus 215 cases in the warfarin group, or a risk reduction of 52 percent.

Omega-3 in fish may reduce breast cancer risk
Wait-and-see approach for prostate cancer questioned for black men
Surgery helps baby with severely swollen head
Face transplant patient celebrates life in public
UK may approve creating babies with DNA from 3 people
More frozen berries recalled over hepatitis A concerns
Woman's 'foot orgasm' is first known case
Good Samaritan who saved drowning girl dies from injuries weeks after rescue
Regulators pave way for biosimilar drug breakthrough
Pennsylvania hospitals' ban on hiring smokers prompts debate
New labels tied to fewer child poisonings by over-the-counter meds
'True Blood' star Joe Manganiello is even tougher than you think
Is your baby overweight? What you need to know
‘Supernanny’ takes on allergies
New clot preventer works as well as warfarin with less bleeding
FDA approves first nonhormonal drug for hot flashe
Differences between the sexes stretches to fitness formulas
Premature ejaculation: Why men should discuss it with their doctors
Tobacco taxes, smoking bans set to save millions of lives, study says
WHO: Treat people with HIV early to stop disease's spread
Fears of MERS virus at Muslim hajj pilgrimage
Parents beware: Kids' wire hampers pose eye dangers
Heat waves: What you need to know
Rare condition causes 16-year-old girl to look like a middle-aged woman
FDA rejects Merck insomnia drug, seeks lower-dose
Watching an avatar may help some lose weight
Painful problem: Why more kids are facing chronic pain
Infertility May Be Linked to Taste Genes
Lawsuit blames Monster energy drinks for California teen's death
Mexico restricts US live hog imports due to piglet virus
Lure, variety of designer drugs is alarming, U.N. agency says
Heart disease deaths show dramatic decline in Europe
6 simple tips for better sleep
Aspirin cuts colon cancer risk, study suggests
A guide to summertime emergencies
Rise in high-end treatment for low-risk prostate cancer
A tongue patch for weight loss?
New 'digital dementia' plaguing young tech users
The scariest infectious diseases right now
Dr. Manny: Marriage equality has health benefits for all
Breakthrough ‘reverse’ vaccine may help combat Type 1 diabetes
More C-sections are now done closer to due date
Melanoma deaths more likely in young men than women
New rules aim to rid schools of junk food
Why carbs may cause food cravings
New way to treat Parkinson's disease
Are Chinese herbs safe to use?
Vietnam War veterans with PTSD have higher risk of heart disease
Heavy drinkers have more post-surgery problems
History of marriage: 13 surprising facts
Drug combo decreases likelihood of stroke for those already at risk
US FDA approves new Baxter drug for hemophilia B